Loading…
DYMISTA CONTROL is a brand name for Fluticasone. The medicine, its uses, side effects and dosage are the same regardless of brand.
Used for: Relief of symptoms of moderate to severe seasonal allergic rhinitis in adults if monotherapy with either intranasal antihistamine or glucocorticoid is not considered sufficient.
Verbatim from this product's MHRA label. Tap a section to expand.
Posology For full therapeutic benefit regular usage is essential. Contact with the eyes should be avoided. Adults One actuation in each nostril twice daily (morning and evening). The maximum daily dose should not exceed 2 sprays in each nostril per day.
Paediatric population Dymista Control Nasal Spray should not be used in children and adolescents under 18 years of age. Elderly No dose adjustment is required in this population. 4). Duration of treatment Treatment should be stopped, or the advice of a doctor sought if an improvement is not seen within 7 days.
This medicine should not be used for more than 3 months continuously without consulting a doctor. Method of administration Dymista Control Nasal Spray is for nasal use only.
Instruction for use Preparing the spray:
The bottle should be shaken gently before use for about 5 seconds by tilting it upwards and downwards and the protective cap be removed afterwards. Prior to first use Dymista Control Nasal Spray must be primed by pressing down and releasing the pump 6 times.
If Dymista Control Nasal Spray has not been used for more than 7 days it must be reprimed once by pressing down and releasing the pump.
Using the spray:
The bottle should be shaken gently before use for about 5 seconds by tilting it upwards and downwards and the protective cap be removed afterwards. After blowing the nose the suspension is to be sprayed once into each nostril keeping the head tilted downward (see figure).
After use the spray tip is to be wiped and the protective cap to be replaced.
Commonly, dysgeusia, a substance-specific unpleasant taste, may be experienced after administration (often due to incorrect method of application, namely tilting the head too far backwards during administration). Adverse reactions are listed below by system organ class and frequency.
7) * A very small number of spontaneous reports have been identified following prolonged treatment with intranasal fluticasone propionate. ** Nasal septal perforation has been reported following the use of intranasal corticosteroids.
4). In rare cases osteoporosis was observed, if nasal glucocorticoids were administered long-term. Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important.
It allows continued monitoring of the benefit/risk balance of the medicinal product. uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
Treatment should be stopped, or the advice of a doctor sought if an improvement is not seen within 7 days. The advice of a doctor or pharmacist should also be sought if symptoms have improved but are not adequately controlled within 7 days.
This medicine should not be used for more than 3 months continuously without consulting a doctor. Medical advice should be sought before using this medicine in the case of; − concomitant use of other corticosteroid products, such as tablets, creams, ointments, asthma medications, similar nasal sprays or eye/nose drops − fever or an infection in the nasal passages or sinuses.
− recent injury or surgery to the nose, or problems with ulceration in the nose. Clinically significant drug interactions in patients receiving fluticasone propionate and ritonavir, resulting in systemic corticosteroid effects including Cushing’s syndrome and adrenal suppression.
5). Systemic effects of nasal corticosteroids may occur, particularly when prescribed at high doses for prolonged periods. These effects are much less likely to occur than with oral corticosteroids and may vary in individual patients and between different corticosteroid preparations.
Potential systemic effects may include Cushing’s syndrome, Cushingoid features, adrenal suppression, growth retardation in children and adolescents, cataract, glaucoma and more rarely, a range of psychological or behavioural effects including psychomotor hyperactivity, sleep disorders, anxiety, depression or aggression (particularly in children).
Dymista Control Nasal Spray undergoes extensive first-pass metabolism, therefore the systemic exposure of intranasal fluticasone propionate in patients with severe liver disease is likely to be increased. This may result in a higher frequency of systemic adverse events.
Caution is advised in these patients. Treatment with higher than recommended doses of nasal corticosteroids may result in clinically significant adrenal suppression. If there is evidence for higher than recommended doses being used, then additional systemic corticosteroid cover should be considered during periods of stress or elective surgery.
1.
Not medical advice. Always read the patient information leaflet and follow your prescriber or pharmacist.
Other brands of Fluticasone in United Kingdom.
Know a brand we are missing in United Kingdom? Suggest a brand →
Brand names are compiled from public regulatory records for active-ingredient mapping only. Drugvu is not affiliated with any manufacturer. This is not medical advice.
In general, the dose of intranasal fluticasone formulations should be reduced to the lowest dose at which effective control of the symptoms of rhinitis is maintained. 2) have not been tested for Dymista Control. As with all intranasal corticosteroids, the total systemic burden of corticosteroids should be considered whenever other forms of corticosteroid treatment are prescribed concurrently.
Visual disturbance may be reported with systemic and topical corticosteroid use. If a patient presents with symptoms such as blurred vision or other visual disturbances, the patient should be considered for referral to an ophthalmologist for evaluation of possible causes which may include cataract, glaucoma or rare diseases such as central serous chorioretinopathy (CSCR) which have been reported after use of systemic and topical corticosteroids.
Close monitoring is warranted in patients with a change in vision or with a history of increased ocular pressure, glaucoma and/or cataracts. If there is any reason to believe that adrenal function is impaired, care must be taken when transferring patients from systemic steroid treatment to Dymista Control Nasal Spray.
In patients who have tuberculosis, any type of untreated infection, or have had a recent surgical operation or injury to the nose or mouth, the possible benefits of the treatment with Dymista Control Nasal Spray should be weighed against possible risk.
Infections of the nasal airways should be treated with antibacterial or antimycotical therapy, but do not constitute a specific contraindication to treatment with Dymista Control Nasal Spray. Dymista Control Nasal Spray contains benzalkonium chloride.
Long term use may cause oedema of the nasal mucosa.